-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Global commercial real estate services and investment company CB Richard Ellis released the "Report on the Development Trends of the Pharmaceutical and Healthcare Industry in the Asia-Pacific Region: Tenant Strategies and Real Estate Investment Opportunities" on the 23rd, showing that as the life sciences industry enters a new round of rapid expansion, the Asia-Pacific region The leasing and investment demand for medical and medical real estate has shown a significant upward trend
The report pointed out that the increase in medical and health consumer spending, changes in demographic trends and government support policies have brought development opportunities for the life sciences industry in the Asia-Pacific region
According to CBRE data, in 2020, as the overall office market in the Asia-Pacific region dropped 25% year-on-year in lease transactions, the organic growth of the life sciences industry and the demand for upgrading and relocation of tenants pushed up the industry's office lease transactions rose by 17.
In terms of logistics and warehousing, some of the specific warehousing requirements derived from the new coronavirus vaccine (especially the mRNA vaccine) have brought opportunities for high-standard logistics warehousing facilities such as cold storage, but the total demand is still relatively limited
In terms of R&D laboratories, many industrial parks in the Asia-Pacific region, including Shanghai Zhangjiang, Beijing Zhongguancun and Suzhou Industrial Park, have provided favorable policies to support the construction of new R&D facilities, thereby driving the continued growth of demand for specific R&D facilities
Xie Chen, head of CBRE China's research department, said: "Mainland China is the world's second largest pharmaceutical market.
For the Shanghai market, CB Richard Ellis research shows that local and multinational pharmaceutical companies maintain the leasing demand for expansion and upgrading, but most multinational companies still adopt the global remote office model
In the Beijing market, CB Richard Ellis found that active investments in the life sciences industry have brought demands for corporate tenants to upgrade office space, and business parks are preferred for the expansion of local pharmaceutical companies
